NTRA News and Press, Natera Inc. From 02/17/22

Natera Announces Results of Large, Multi-Center Clinical Experience Study Showing Excellent Positive Predictive Value of the Prospera™ Kidney Test PR Newswire AUSTIN, Texas , Feb. 17, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in...

Landmark CIRCULATE-Japan Study Shows Natera's Signatera™ MRD Test is Predictive of Chemotherapy Benefit in Colorectal Cancer Analysis of 1,000+ patients, with 12 months mean follow up, demonstrates clinical utility of Signatera for informing post-surgical treatment decisi...

Blinded, prospective, multi-site trial shows the most common microdeletion can be detected non-invasively with a low false positive rate Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced the publication of the landmark...

Natera to Present Latest Signatera™ MRD Data in Colorectal and Pancreatic Cancers at the ASCO GI Symposium 2022, and Host Special Investor Call Oral presentations to include largest analysis to date from the prospective CIRCULATE-Japan study and results from first study s...

Dr. Alexey Aleshin to take on new role as GM of early cancer detection at Natera Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced its expansion into the early cancer detection (ECD) market to advance the companyȁ...

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Natera, Inc. (“Natera” or the “Company”) (NASDAQ: NTRA) on behalf of Natera stockholders. Our investigation concerns whether Natera...

Natera to Webcast Live Presentation at the 40th Annual J.P. Morgan Healthcare Conference PR Newswire AUSTIN, Texas , Jan. 4, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced that ...

Signatera™ Wins Fierce Life Sciences Innovation Award Natera's personalized MRD test selected as winner in the Medical Device Innovation category PR Newswire AUSTIN, Texas , Jan. 3, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in ...

Look for surprise values in underpriced stocks. Not the story issues being bally-hooed by touts and the media – everyone knows them. The hidden values are ones found by experienced professional researchers who know the details of industry group issues and their special strength...

Natera Presents Latest Signatera™ MRD Data in Breast Cancer at SABCS 2021 PR Newswire AUSTIN, Texas , Dec. 9, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced its latest fin...